[HIV seropositivity in blood donors from 1990 to 1992: prevalence, estimation of residual risk of transfusion-related infections and epidemiology] NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[HIV seropositivity in blood donors from 1990 to 1992: prevalence, estimation of residual risk of transfusion-related infections and epidemiology]

Rev Fr Transfus Hemobiol. 1993 Jul;36(4):327-37. Unique Identifier : AIDSLINE MED/93363121
Courouce AM; Institut National de Transfusion Sanguine, Paris.

Abstract: In France, HIV seroprevalence in blood donations still decreased from 1990 to 1992 with an important diminution in 1992, in first time donors as well as in regular donors. During the last 1992 semester, this prevalence reached 0.051%: 0.19% and 0.026% in donations from first time and regular donors respectively. The residual risk was estimated to be 1 for 580,000 donations in 1992 (CI 95% = 1/2,000,000 to 1/330,000). Sex ratio was 3.7 and 3.4 in 1990 and 1991 and increased to 5.5 in 1992 due to a very small number of seropositive women, which seems to be an important epidemiological indicator. The major at-risk group is still represented by homo-bisexual men.
Keywords: Adolescence Adult Blood Transfusion/*ADVERSE EFFECTS English Abstract Female France/EPIDEMIOLOGY Human HIV Infections/*TRANSMISSION HIV Seropositivity/*EPIDEMIOLOGY *HIV Seroprevalence Male Retrospective Studies Risk Factors JOURNAL ARTICLEKWDadolescenceadultbloodtransfusion/KWDadverseeffectsenglishabstractfemalefrance/epidemiologyhumanhivinfections/KWDtransmissionhivseropositivity/KWDepidemiologyKWDhivseroprevalencemaleretrospectivestudiesriskfactorsjournalarticle
931230
M93C0763

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .